Interleukin‐2 receptor antagonists: Protective factors against new‐onset diabetes after renal transplantation: 白细胞介素2受体拮抗剂:肾移植后新发糖尿病的保护因素. Issue 11 (19th April 2018)

• Record Type: Journal Article
• Authors: Xue, Mengjuan; Zhao, Chenhe; Lv, Chaoyang; Chen, Minling; Xu, Ming; Rong, Ruiming; Zhang, Yao; Liang, Jing; Gao, Jian; Yu, Mingxiang; Zhu, Tongyu; Gao, Xin
• Is Part Of: Journal of diabetes. Volume 10:Issue 11(2018)
• Page Start: 857
• Page End: 865
• Publication Date: 2018-04-19
• Subjects: interleukin‐2 -- kidney transplantation -- new‐onset diabetes after transplantation -- receptor antagonists; 白细胞介素2 -- 肾移植 -- 移植后新发糖尿病 -- 受体拮抗剂; Diabetes -- Periodicals; 618.3646005
• DOI: 10.1111/1753-0407.12663
• Languages: English
• ISSNs: 1753-0393

Abstract

Abstract: Background: The aim of the present study was to examine the association between interleukin‐2 receptor antagonists (IL‐2Ra) and new‐onset diabetes after transplantation (NODAT) among renal transplant recipients (RTRs). Methods: Between January 1993 and March 2014, 915 patients underwent renal transplantation at Zhongshan Hospital. In all, 557 RTRs were included in the present retrospective cohort study. The incidence of NODAT in this cohort was determined and multivariate Cox regression analysis was used to evaluate the risk factors for NODAT and to show the association between IL‐2Ra use and NODAT development among RTRs. The cumulative incidence of NODAT was compared between groups treated with or without IL‐2Ra. Results: The mean ±SD postoperative follow‐up was 5.08 ±3.17 years. The incidence of NODAT at the end of follow‐up was 20.3%. After adjusting for potential confounders in the multivariate logistic regression (i.e. age, sex, body mass index, history of smoking, family history of diabetes, duration of dialysis, type of dialysis, donor type, recovery of graft function, acute rejection, hepatitis B or C or cytomegalovirus infection, fasting plasma glucose levels before and 1 week after transplantation, preoperative total cholesterol and triglyceride levels, daily dose of glucocorticoid, immunosuppressive regimen type, and immunosuppressant concentration after transplantation), IL‐2Ra use was found to be related to a reduced incidence of NODAT. Conclusions: Use of IL‐2Ra is associated with protection against the development of NODAT in RTRs. Abstract : Highlights Previous findings regarding the relationship between interleukin‐2 receptor antagonists (IL‐2Ra) and new‐onset diabetes after transplantation (NODAT) are controversial. This study reveals that the use of IL‐2Ra protects against the development of NODAT in renal transplant recipients.